David Hallal has served as Chief Executive Officer of Scholar Rock since April 2025. He has served as Chairman of Scholar Rock’s Board of Directors since July 2017. David is a proven 30-year veteran in the biopharmaceutical industry, having grown and operated several successful biotechnology companies.
Previously, he served as Chief Executive Officer & Chairman of ElevateBio, a cell and gene therapy company. Prior to ElevateBio, David spent more than a decade at Alexion Pharmaceuticals as Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer and played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenues by 2016. As the CEO of Alexion, David transitioned the company from a single product to a multi-product enterprise.
Prior to Alexion, David held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology, and ophthalmology, as the Vice President of Sales at OSI Eyetech and at Biogen where he led the immunology sales team. Prior to Biogen, David also held various leadership roles at Amgen.
He also serves as the Chairman of the Board of Directors of ElevateBio, Chairman of the Board of Directors of iTeos Therapeutics SA and as a member of the Board of Directors of Seer Biosciences, Inc. David holds a BA in psychology from the University of New Hampshire.
What is David Hallal's net worth?
The estimated net worth of David Hallal is at least $69.33 million as of January 13th, 2026. Mr. Hallal owns 1,541,645 shares of Scholar Rock stock worth more than $69,327,776 as of January 19th. This net worth evaluation does not reflect any other investments that Mr. Hallal may own. Learn More about David Hallal's net worth.
How do I contact David Hallal?
Has David Hallal been buying or selling shares of Scholar Rock?
Over the course of the past ninety days, David Hallal has sold $2,453,115.00 in Scholar Rock stock. Most recently, David Hallal sold 57,450 shares of the business's stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a transaction totalling $2,453,115.00. Following the completion of the sale, the chief executive officer now directly owns 1,541,645 shares of the company's stock, valued at $65,828,241.50. Learn More on David Hallal's trading history.
Who are Scholar Rock's active insiders?
Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), David Hallal (CEO), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), Vikas Sinha (CFO), Akshay Vaishnaw (President, R&D), Keith Woods (COO), and Keith Woods (COO). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?
In the last year, Scholar Rock insiders bought shares 3 times. They purchased a total of 530,038 shares worth more than $19,988,928.11. In the last year, insiders at the sold shares 27 times. They sold a total of 618,391 shares worth more than $24,126,909.07. The most recent insider tranaction occured on January, 14th when insider Mo Qatanani sold 13,112 shares worth more than $592,662.40. Insiders at Scholar Rock own 13.3% of the company.
Learn More about insider trades at Scholar Rock. Information on this page was last updated on 1/14/2026.
